Recent reports show that a) COVID-19 patients requiring intensive care unit (ICU) have increased level of GM-CSF in China and b) drugs targeting CSF2 (GM-CSF) or its receptor (such as lenzilumab, namilumab, gimsilumab, and otilimab) are being evaluated in clinical trials with COVID-19 patients13–15,30. This evidence concerns the gene CSF2 and COVID-19.